Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > TO CLARIFY: OSC & IIROC CRACKDOWN HELPS THE ENTIRE MARKET.

<< Previous

Bullboard Posts

Next >>

Comment by Raddnaron Dec 20, 2020 10:38am

93 Views

Post# 32148957

RE:TO CLARIFY: OSC & IIROC CRACKDOWN HELPS THE ENTIRE MARKET.

Big A, I have a feeling it's you on yahoo board. If it's you, I think you'll understand the context. If so, let me know if you want me to delete my post asking if it's you. Glad to have you there. We could really use your DD you share on the other boards lol.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023